Clinical Trial
doi: 10.1097/00004714-200110000-00005.
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia
Affiliations
- PMID: 11593073
- DOI: 10.1097/00004714-200110000-00005
Item in Clipboard
Clinical Trial
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia
J Clin Psychopharmacol.
2001 Oct.
Abstract
CX516, a positive modulator of the glutamatergic alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, improves performance in tasks requiring learning and memory in animals. CX516 was added to clozapine in 4-week, placebo-controlled, dose-finding (N = 6) and fixed-dose (N = 13) trials. CX516 was tolerated well and was associated with moderate to large, between-group effect sizes compared with placebo, representing improvement in measures of attention and memory. These preliminary results suggest that CX516 and other "ampakines" hold promise for the treatment of schizophrenia.
Similar articles
-
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.Neuropsychopharmacology. 2008 Feb;33(3):465-72. doi: 10.1038/sj.npp.1301444. Epub 2007 May 9. Neuropsychopharmacology. 2008. PMID: 17487227 Free PMC article. Clinical Trial.
-
Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series.Schizophr Res. 2002 Oct 1;57(2-3):221-6. doi: 10.1016/s0920-9964(01)00311-5. Schizophr Res. 2002. PMID: 12223253 Clinical Trial.
-
Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.Schizophr Bull. 2012 Sep;38(5):1003-11. doi: 10.1093/schbul/sbr004. Epub 2011 Mar 21. Schizophr Bull. 2012. PMID: 21422107 Free PMC article. Review.
-
A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.J Clin Psychiatry. 2006 Dec;67(12):1912-9. J Clin Psychiatry. 2006. PMID: 17194269 Clinical Trial.
-
Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Clin Ther. 2008. PMID: 18840365 Review.
Cited by
-
Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report.J Mol Neurosci. 2002 Aug-Oct;19(1-2):197-200. doi: 10.1007/s12031-002-0032-4. J Mol Neurosci. 2002. PMID: 12212780 Clinical Trial.
-
The neuropharmacology of implicit learning.Curr Neuropharmacol. 2010 Dec;8(4):367-81. doi: 10.2174/157015910793358178. Curr Neuropharmacol. 2010. PMID: 21629444 Free PMC article.
-
Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps.Psychopharmacology (Berl). 2009 Jan;202(1-3):15-36. doi: 10.1007/s00213-008-1365-7. Epub 2008 Nov 15. Psychopharmacology (Berl). 2009. PMID: 19011839 Review.
-
Gamma oscillation deficits and the onset and early progression of schizophrenia.Harv Rev Psychiatry. 2010 May-Jun;18(3):173-89. doi: 10.3109/10673221003747609. Harv Rev Psychiatry. 2010. PMID: 20415633 Free PMC article.
-
Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy.Br J Psychiatry. 2013 Sep;203(3):172-8. doi: 10.1192/bjp.bp.111.107359. Br J Psychiatry. 2013. PMID: 23999481 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
